Literature DB >> 33352742

OSmfs: An Online Interactive Tool to Evaluate Prognostic Markers for Myxofibrosarcoma.

Huimin Li1, Longxiang Xie1, Qiang Wang1, Yifang Dang1, Xiaoxiao Sun1, Lu Zhang1, Yali Han1, Zhongyi Yan1, Huan Dong1, Hong Zheng1, Yongqiang Li1, Wan Zhu2, Xiangqian Guo1.   

Abstract

Myxofibrosarcoma is a complex genetic disease with poor prognosis. However, more effective biomarkers that forebode poor prognosis in Myxofibrosarcoma remain to be determined. Herein, utilizing gene expression profiling data and clinical follow-up data of Myxofibrosarcoma cases in three independent cohorts with a total of 128 Myxofibrosarcoma samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we constructed an easy-to-use web tool, named Online consensus Survival analysis for Myxofibrosarcoma (OSmfs) to analyze the prognostic value of certain genes. Through retrieving the database, users generate a Kaplan-Meier plot with log-rank test and hazard ratio (HR) to assess prognostic-related genes or discover novel Myxofibrosarcoma prognostic biomarkers. The effectiveness and availability of OSmfs were validated using genes in ever reports predicting the prognosis of Myxofibrosarcoma patients. Furthermore, utilizing the cox analysis data and transcriptome data establishing OSmfs, seven genes were selected and considered as more potentially prognostic biomarkers through overlapping and ROC analysis. In conclusion, OSmfs is a promising web tool to evaluate the prognostic potency and reliability of genes in Myxofibrosarcoma, which may significantly contribute to the enrichment of novelly potential prognostic biomarkers and therapeutic targets for Myxofibrosarcoma.

Entities:  

Keywords:  Myxofibrosarcoma; OSmfs; prognostic markers; tool

Year:  2020        PMID: 33352742      PMCID: PMC7766036          DOI: 10.3390/genes11121523

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  39 in total

1.  MMP13 is a potential prognostic marker for colorectal cancer.

Authors:  Ming-Yii Huang; Hui-Jen Chang; Fu-Yen Chung; Ming-Je Yang; Yu-Hsiang Yang; Jaw-Yuan Wang; Shiu-Ru Lin
Journal:  Oncol Rep       Date:  2010-11       Impact factor: 3.906

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Prognostic impact of CD109 expression in myxofibrosarcoma.

Authors:  Makoto Emori; Tomohide Tsukahara; Kenji Murata; Shintaro Sugita; Tomoko Sonoda; Mitsunori Kaya; Tamotsu Soma; Mikito Sasaki; Satoshi Nagoya; Tadashi Hasegawa; Takuro Wada; Noriyuki Sato; Toshihiko Yamashita
Journal:  J Surg Oncol       Date:  2015-05-28       Impact factor: 3.454

4.  Inhibition of cell proliferation and migration in non‑small cell lung cancer cells through the suppression of LYPLA1.

Authors:  Anaz Mohammed; Caixin Zhang; Shuwen Zhang; Qin Shen; Jieying Li; Zhiyuan Tang; Hua Liu
Journal:  Oncol Rep       Date:  2018-11-09       Impact factor: 3.906

Review 5.  Myxofibrosarcoma.

Authors:  Christina L Roland; Wei-Lien Wang; Alexander J Lazar; Keila E Torres
Journal:  Surg Oncol Clin N Am       Date:  2016-07-30       Impact factor: 3.495

6.  Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.

Authors:  Hsuan-Ying Huang; Hong-Yo Kang; Chien-Feng Li; Hock-Liew Eng; Shih-Cheng Chou; Ching-Nan Lin; Ching-Yeh Hsiung
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

7.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

8.  OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients.

Authors:  Guosen Zhang; Qiang Wang; Mengsi Yang; Quan Yuan; Yifang Dang; Xiaoxiao Sun; Yang An; Huan Dong; Longxiang Xie; Wan Zhu; Yunlong Wang; Xiangqian Guo
Journal:  Front Oncol       Date:  2019-06-04       Impact factor: 6.244

9.  Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix.

Authors:  Stefan M Willems; Alex B Mohseny; Crina Balog; Raj Sewrajsing; Inge H Briaire-de Bruijn; Jeroen Knijnenburg; Anne-Marie Cleton-Jansen; Raf Sciot; Christopher D M Fletcher; André M Deelder; Karoly Szuhai; Paul J Hensbergen; Pancras C W Hogendoorn
Journal:  J Cell Mol Med       Date:  2009-03-13       Impact factor: 5.310

10.  Integrated genetic and epigenetic analysis of myxofibrosarcoma.

Authors:  Koichi Ogura; Fumie Hosoda; Yasuhito Arai; Hiromi Nakamura; Natsuko Hama; Yasushi Totoki; Akihiko Yoshida; Momoko Nagai; Mamoru Kato; Erika Arakawa; Wakako Mukai; Hirofumi Rokutan; Akira Kawai; Sakae Tanaka; Tatsuhiro Shibata
Journal:  Nat Commun       Date:  2018-07-17       Impact factor: 14.919

View more
  1 in total

Review 1.  Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.

Authors:  Silvia Vanni; Alessandro De Vita; Lorena Gurrieri; Valentina Fausti; Giacomo Miserocchi; Chiara Spadazzi; Chiara Liverani; Claudia Cocchi; Chiara Calabrese; Alberto Bongiovanni; Nada Riva; Laura Mercatali; Federica Pieri; Roberto Casadei; Enrico Lucarelli; Toni Ibrahim
Journal:  Ther Adv Med Oncol       Date:  2022-06-28       Impact factor: 5.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.